Along with imaging techniques, the presence of circulatory nuclear matrix proteins (e.g., NMP22, NuMA, lamin B1) in the body fluids (plasma, urine, saliva, etc.)is used as a biomarker for diagnosis and prognosis of many cancer types, including prostate, bladder, colorectal, hepatic, head and neck cancers [167,168,169,170,171]. Here, NUMA1 is linked to cancer.